Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.97
−$0.05 · -1.66%
GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based in Edinburgh, United Kingdom.
Previous close
$2.97
−$0.05 · -1.66%
Pre-market
$2.80
−$0.17 · -5.72%
Sep 11, 5:50 AM ET
Regular session · ET · Market data may be delayed.
GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based in Edinburgh, United Kingdom.
Day range
Current $2.97
52-week range
Current $2.97
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
8
Overpriced
Sentiment
50
Mixed
Risk
71
High Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based in Edinburgh, United Kingdom.
Day range
Current $2.97
52-week range
Current $2.97
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 36.25K USD | — | — | — | — |
| Cost of goods sold | 1.27M USD | 48.95K USD | — | — | — |
| Gross profit | −1.23M USD | −48.95K USD | — | — | — |
| Research and development | 925.48K USD | 903.94 USD | 5.03M USD | 691.26K USD | 38.32M USD |
| Selling, general, and administrative | 5.5M USD | 14.72M USD | 10.74M USD | 11.99M USD | 18.38M USD |
| Operating expenses | 5.85M USD | 15.62M USD | 15.77M USD | 12.68M USD | 59.06M USD |
| Interest income | — | 875 USD | 2.53K USD | 8.42K USD | 1.17K USD |
| Interest expense | 490.84K USD | — | 22.46K USD | 15.88K USD | 11.24K USD |
| Depreciation and amortization | 574.71K USD | 48.95K USD | 29.27K USD | 29.27K USD | 542.26K USD |
| Operating income | −7.08M USD | −15.62M USD | −15.77M USD | −12.68M USD | −59.06M USD |
| Net income | −6.39M USD | −18.06M USD | −15.79M USD | −14.63M USD | −58.54M USD |
Company facts updated Sep 11, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
